Screener
Bausch + Lomb BLCO Pharmaceuticals — Goodwill
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch + Lomb in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The source filing: Bausch + Lomb’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001860742-26-000088
| (in millions) | Vision Care | Pharmaceuticals | Surgical | Total |
|---|---|---|---|---|
| Balance, January 1, 2025 | $3,529 | $644 | $350 | $4,523 |
| Acquisitions (Note 5) | — | — | 97 | 97 |
| Foreign exchange and other | 26 | 100 | 12 | 138 |
| Balance, December 31, 2025 | 3,555 | 744 | 459 | 4,758 |
| Acquisitions | 4 | — | — | 4 |
| Foreign exchange and other | (11) | (24) | (4) | (39) |
| Balance, June 30, 2026 | $3,548 | $720 | $455 | $4,723 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Bausch + Lomb's pharmaceuticals — goodwill?
- Bausch + Lomb (BLCO) reported pharmaceuticals — goodwill of $720M in Q2 2026.
- How has Bausch + Lomb's pharmaceuticals — goodwill changed year-over-year?
- Bausch + Lomb's pharmaceuticals — goodwill decreased by 3.7% year-over-year, from $748M to $720M.
- What does pharmaceuticals — goodwill mean?
- Represents the intangible asset value recorded when the pharmaceutical segment is acquired for a price exceeding the fair market value of its identifiable net assets. This reflects the premium paid for brand reputation, customer relationships, and intellectual property within the ophthalmic pharmaceutical business.
Ask your AI about Bausch + Lomb's pharmaceuticals — goodwill.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude